| HOME >> BIOLOGY >> TECHNOLOGY |
BETHLEHEM, Pa., April 28 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Robert W. Lee, Ph.D. to the position of Vice President, Pharmaceutical Development.
Dr. Lee joins Particle Sciences following more than 17 years experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents. Most recently, he served Novavax, Inc. as Vice President of Pharmaceutical Development. Prior to that, Dr. Lee held senior management positions at Lyotropic Therapeutics, Inc. and IMCOR Pharmaceutical Co. Dr. Lee is currently serving as a scientific advisor for NanoScan Imaging, LLC, and Savara Pharmaceutical.
From 1990 to 2002, Dr. Lee held various R&D positions within Sterling Winthrop Pharmaceuticals Research Division, NanoSystems, and elan Drug Delivery, Inc. His areas of expertise include Preformulation, drug delivery, formulation development, analytical sciences, sterile manufacturing, and technology evaluation and development. Dr. Lee was one of the founding members of NanoSystems, a drug delivery company focused on the formulation of water-insoluble drugs. He maintains strong academic ties, including an appointment as Adjunct Associate Professor of Pharmaceutical Chemistry at the University of Kansas in 1992, and serving as a reviewer for both the International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.
Dr. Mitchnick comments that "Robert brings a wealth of experience to the Particle Sciences team. His background fits perfectly with our continued focus on advanced delivery systems. Particle Sciences typically deals with difficult to solubilize API's and nanotechnology based systems. Rob has deep experience in these areas as well as in clinical trial manufacturing, another area in which Particle sciences is expanding."
Dr. Lee received a Ph.D. in Physical Bioorganic Chemistry under the
direction of Professor Thomas C. Bruice from the University of Califo
'/>"/>
| SOURCE Particle Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved |